B. Riley Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $32.00

Oppenheimer initiated coverage of Aardvark Therapeutics with a rating of Outperform and set a new price target of $35.00

William Blair initiated coverage of Aardvark Therapeutics with a rating of Outperform

Raymond James initiated coverage of Aardvark Therapeutics with a rating of Strong Buy and set a new price target of $47.00

BTIG Research initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $26.00

Stifel initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $24.00

H.C. Wainwright initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $40.00

Morgan Stanley initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $29.00

BofA Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $22.00

Cantor Fitzgerald initiated coverage of Aardvark Therapeutics with a rating of Overweight and set a new price target of $50.00

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension (NCT0719703

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that (i) on February 9, 2026, five new employees were granted inducement awards consisting of stock options to purchase an aggregate of 147,213 shares of common stock and (ii) on February 11, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 5,125 shares of common stock.   Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Induceme

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that it has established Ardia Therapeutics, Inc. (Ardia), a new wholly-owned U.S. subsidiary. Ardia will support development of a new dermatology pipeline focused on lead asset, DIA-615, a potential topical treatment for a variety of inflammatory skin diseases, including psoriasis. Bryan Jones, Ph.D., has been named Chief Executive Officer of Ardia and has transitioned out of his current role at Aar

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial SAN DIEGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that the first patient has been dosed in Australia in its Phase 3 HERO pivo

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during December: Piper Sandler 37th Annual Healthcare Conference in New YorkPresentation: Wednesday, December 3 at 8:00 a.m. ETEvercore ISI 8th Annual Healthcare Conference in MiamiPresentation: Thursday, December 4 at 11:15 a.m. ET Live webcasts of each presentation will be accessible on the company's website, www.aardvarktherapeutics.com, under the i

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced glucose control, along with preservation of lean body mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape Oral ARD-201 shows potential for weight management after GLP-1RA discontinuation, supported by new promising preclinical results and ARD-101 clinical data $126.4 million in cash, cash equivalents, and

SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on November 10, 2025, one new employee was granted an inducement award consisting of a stock option to purchase 4,881 shares of common stock. The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee's employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape  Preclinical and clinical data demonstrates the potential of ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after the discontinuation of GLP-1RA Aardvark to host investor webinar on November 5th, 2025 to review ARD-101 and ARD-201 programs, as well as ObesityWeek presentations SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on develop

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)

SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. "It's an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS," said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. "The United in